Schering’s HCV combo gains indication
Executive Summary
FDA approves new labeling for Schering-Plough's PegIntron (peginterferon alfa-2b) and Rebetol (ribavirin) combination therapy for treating chronic hepatitis C in patients with compensated liver disease, making it the first HCV combination approved in the U.S. that is not restricted to treatment-naïve patients. The label expansion, approved days after the announcement that Schering will merge with Merck, comes as the firm is moving ahead with Phase III trials of its direct antiviral for HCV, the protease inhibitor boceprevir
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 9 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.